Oramed Pharmaceuticals Inc
NASDAQ:ORMP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Oramed Pharmaceuticals Inc
Short-Term Debt
Oramed Pharmaceuticals Inc
Short-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Short-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Oramed Pharmaceuticals Inc
NASDAQ:ORMP
|
Short-Term Debt
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Short-Term Debt
$6.5B
|
CAGR 3-Years
-27%
|
CAGR 5-Years
85%
|
CAGR 10-Years
N/A
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Short-Term Debt
$284m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
N/A
|
|
|
|
Pfizer Inc
NYSE:PFE
|
Short-Term Debt
$157m
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-26%
|
CAGR 10-Years
N/A
|
|
|
Merck & Co Inc
NYSE:MRK
|
Short-Term Debt
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Short-Term Debt
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Oramed Pharmaceuticals Inc
Glance View
Oramed Pharmaceuticals, Inc. engages in the provision of oral delivery solutions for drugs delivered via injection. The company is headquartered in New York City, New York and currently employs 13 full-time employees. The company went IPO on 2002-04-01. The firm is engaged in the research and development of pharmaceutical solutions, including an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides. The firm has three product pipelines: ORMD-0801 type 2, ORMD-0801 type 1 and ORMD-0901. ORMD-0801 allows insulin to travel from the gastrointestinal tract via the portal vein to the bloodstream, where the insulin is delivered. The company is in Phase III of clinical trials. ORMD-0901 (GLP-1 capsule), aids in the balance of blood-sugar levels and decreases appetite. The firm is also engaged in the research and development of an oral vaccine for COVID-19 through its subsidiary Oravax Medical Inc., or Oravax.
See Also
What is Oramed Pharmaceuticals Inc's Short-Term Debt?
Short-Term Debt
0
USD
Based on the financial report for Dec 31, 2024, Oramed Pharmaceuticals Inc's Short-Term Debt amounts to 0 USD.
